SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-036613
Filing Date
2024-04-26
Accepted
2024-04-26 16:01:17
Documents
14
Period of Report
2024-04-24
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0204623-8k_adialphar.htm   iXBRL 8-K 28438
2 SEPARATION AGREEMENT BETWEEN ADIAL PHARMACEUTICALS, INC. AND DR. BANKOLE JOHNSON ea020462301ex10-1_adial.htm EX-10.1 69045
  Complete submission text file 0001213900-24-036613.txt   289377

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE adil-20240424.xsd EX-101.SCH 3024
4 XBRL LABEL FILE adil-20240424_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE adil-20240424_pre.xml EX-101.PRE 22365
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0204623-8k_adialphar_htm.xml XML 3771
Mailing Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901
Business Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901 434-422-9800
ADIAL PHARMACEUTICALS, INC. (Filer) CIK: 0001513525 (see all company filings)

IRS No.: 800667150 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38323 | Film No.: 24883385
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)